Exclusive Commercialization Partnership With Clinigen for Xervyteg® in aGvHD

Enhancing Survival Through Innovative Immune Modulation

We are a clinical-stage microbiome therapeutics company
aiming to improve survival in cancer.

Our strengths

A full ecosystem approach

Oncology focused

AI-Powered Drug Development

cGMP Versatile Manufacturing Capacities

Latest News

October 7, 2025

October 7, 2025: MaaT Pharma Announces Positive Second Safety Interim Analysis from DSMB for Phase 2b PHOEBUS Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT

September 23, 2025

September 22, 2025: Interview of Eric Soyer, CFO at MaaT Pharma – Boursier.com (French Only)

September 17, 2025

September 17, 2025: MaaT Pharma Publishes its Half Year 2025 Results and Provides a Business Update

Like what you see? See more posts

Our upcoming events

Event
October 14, 2025

SITC 2025

SITC 2025 - November 5-9, 2025 - National Harbor, MD
MaaT Pharma
Event
October 14, 2025

SFGM-TC 2025

SFGM-TC 2025 - November 19-21, 2025
MaaT Pharma
Event
October 14, 2025

Investir Day 2025

Investir Day 2025 - November 25, 2025
MaaT Pharma

Join the MaaT Pharma adventure!

Bring your talents, your passion and join an inclusive, creative, and multidisciplinary team. We aim to leverage the potential of microbiome to improve the treatment of patients with cancer.

Learn more about our values, our environment and see what we have to offer to you!

Careers